Drugs / vercirnon
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01827631 | May → Jun 2013 | Crohn disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01489943 | Sep → Nov 2011 | Crohn disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01611805 | Jul → Oct 2010 | Crohn disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01114607 | May → Jun 2010 | Crohn disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT00540657 | Oct 2007 → Jun 2008 | celiac disease | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00306215 | Mar 2006 → Aug 2008 | Crohn disease | Amgen | Completed | Missed primary |
| Phase 2 | NCT00102921 | Aug 2004 → Dec 2005 | Crohn disease | Amgen | Completed | No outcome recorded |
| Phase 34 trials · 3 missed | ||||||
| Phase 3 | NCT01536418 | Nov 2011 → Oct 2013 | Crohn disease | GlaxoSmithKline | Terminated | Missed primary |
| Phase 3 | NCT01316939 | May 2011 → Oct 2013 | Crohn disease | GlaxoSmithKline | Terminated | Missed primary |
| Phase 3 | NCT01318993 | Apr 2011 → Sep 2013 | Crohn disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT01277666 | Dec 2010 → Jul 2013 | Crohn disease | GlaxoSmithKline | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01658605 Comparator | Feb 2013 | ulcerative colitis | GlaxoSmithKline | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-08-23 | GlaxoSmithKline | Results GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint gsk.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-08-23 | GlaxoSmithKline | GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint gsk.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vercirnon | “CCX282-B, also called vercirnon, is a specific, orally-administered chemokine receptor CCR9 antagonist that regulates migration and activation of inflammatory cells in the intestine.” PMID 23527300 ↗ Mar 2013 |
| Known as | CCX282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178578 ↗ |
| Known as | CCX282-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306215 ↗ |
| Known as | GSK1605786 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01827631 ↗ |
| Known as | GSK1605786A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536418 ↗ |
| Known as | VERCIRNON SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178578 ↗ |
| Known as | Verecimon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178578 ↗ |
| Action | Inhibit | “CCX282-B is a highly potent, orally active, chemokine receptor antagonist” NCT00102921 ↗ |
| Modality | Small molecule | — CHEMBL2178578 ↗ |
| Route | Oral | “daily oral doses of CCX282-B” NCT00102921 ↗ |
| Target | CCR9 | “whose single target is the G-protein coupled receptor CCR9.” NCT00102921 ↗ |